Survey on the Initiation of Aripiprazole Once-Monthly via a Two-Injection Start in Adult Patients with Schizophrenia: Experience of European Healthcare Professionals

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-03-03 DOI:10.1007/s12325-025-03130-w

Andrea Fagiolini, Karolina Leopold, Sofia Pappa, William J. Cottam, Joe Hickey, Olivia Rogerson, Murat Yildirim, Clodagh Beckham

{"title":"Survey on the Initiation of Aripiprazole Once-Monthly via a Two-Injection Start in Adult Patients with Schizophrenia: Experience of European Healthcare Professionals","authors":"Andrea Fagiolini, Karolina Leopold, Sofia Pappa, William J. Cottam, Joe Hickey, Olivia Rogerson, Murat Yildirim, Clodagh Beckham","doi":"10.1007/s12325-025-03130-w","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable (LAI) for the maintenance treatment of adults with schizophrenia. The AOM 400 two-injection start initiation regimen (AOM 400-TIS) is an alternative to treatment initiation with one injection of AOM 400 plus 14 days of oral aripiprazole supplementation. This survey investigated the real-world experiences of European healthcare professionals (HCPs) with AOM 400-TIS.</p><h3>Methods</h3><p>Physicians and nurses in Germany, Italy, and the United Kingdom who had prescribed and/or administered AOM 400-TIS ≥ 3 times to patients with schizophrenia were invited to participate in an online survey. The primary objective was to investigate HCPs’ experiences and satisfaction with AOM 400-TIS. Descriptive analysis was performed on data collected between 1 February and 21 March 2024.</p><h3>Results</h3><p>Data from 94 HCPs were analysed. Most were psychiatrists (62.8%) or psychiatric nurses (29.8%) who worked in specialist mental health clinics/centres (59.6%) or hospitals (inpatient, 36.2%; outpatient, 23.4%). Median duration in clinical practice was 21.0 years. Common reasons for initiating AOM 400-TIS were poor adherence (85.1%), relapse (59.6%), and high hospitalisation rates (48.9%). Common prescribing goals for AOM 400-TIS included improving adherence (70.2%), preventing relapses (69.1%), and improving patient quality of life (62.8%). Barriers to AOM 400-TIS were patients not wanting two injections (66.0%), tolerability concerns (30.9%), and safety concerns regarding administration of a high dose on a single day (28.7%). Key factors influencing prescription of AOM 400-TIS were prior treatment adherence (55.3%) and efficacy (48.9%). Most HCPs agreed/strongly agreed that AOM 400-TIS was easy to administer (79.8%) and had a similar safety/tolerability profile to the one-injection start regimen (69.1%), with the majority satisfied with patient outcomes with AOM 400-TIS (84.0%).</p><h3>Conclusions</h3><p>European HCPs reported that AOM 400-TIS was easy to administer, well tolerated, and improved treatment outcomes. Barriers to its use included patient reluctance and perceived safety concerns.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 4","pages":"1935 - 1949"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03130-w.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03130-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable (LAI) for the maintenance treatment of adults with schizophrenia. The AOM 400 two-injection start initiation regimen (AOM 400-TIS) is an alternative to treatment initiation with one injection of AOM 400 plus 14 days of oral aripiprazole supplementation. This survey investigated the real-world experiences of European healthcare professionals (HCPs) with AOM 400-TIS.

Methods

Physicians and nurses in Germany, Italy, and the United Kingdom who had prescribed and/or administered AOM 400-TIS ≥ 3 times to patients with schizophrenia were invited to participate in an online survey. The primary objective was to investigate HCPs’ experiences and satisfaction with AOM 400-TIS. Descriptive analysis was performed on data collected between 1 February and 21 March 2024.

Results

Data from 94 HCPs were analysed. Most were psychiatrists (62.8%) or psychiatric nurses (29.8%) who worked in specialist mental health clinics/centres (59.6%) or hospitals (inpatient, 36.2%; outpatient, 23.4%). Median duration in clinical practice was 21.0 years. Common reasons for initiating AOM 400-TIS were poor adherence (85.1%), relapse (59.6%), and high hospitalisation rates (48.9%). Common prescribing goals for AOM 400-TIS included improving adherence (70.2%), preventing relapses (69.1%), and improving patient quality of life (62.8%). Barriers to AOM 400-TIS were patients not wanting two injections (66.0%), tolerability concerns (30.9%), and safety concerns regarding administration of a high dose on a single day (28.7%). Key factors influencing prescription of AOM 400-TIS were prior treatment adherence (55.3%) and efficacy (48.9%). Most HCPs agreed/strongly agreed that AOM 400-TIS was easy to administer (79.8%) and had a similar safety/tolerability profile to the one-injection start regimen (69.1%), with the majority satisfied with patient outcomes with AOM 400-TIS (84.0%).

Conclusions

European HCPs reported that AOM 400-TIS was easy to administer, well tolerated, and improved treatment outcomes. Barriers to its use included patient reluctance and perceived safety concerns.

查看原文本刊更多论文

成年精神分裂症患者通过两次注射开始每月一次阿立哌唑的调查：欧洲医疗保健专业人员的经验。

阿立哌唑每月一次400 mg （aom400）是一种用于成人精神分裂症患者维持治疗的长效注射剂（LAI）。aom400两针起始治疗方案（aom400 - tis）是一种替代方案，即一针aom400加14天口服阿立普拉唑。这项调查调查了欧洲医疗保健专业人员（HCPs）与aom400 - tis的实际经验。方法：邀请德国、意大利和英国为精神分裂症患者开具和/或使用AOM 400-TIS≥3次的医生和护士参加在线调查。主要目的是调查医护人员对aom400 - tis的体验和满意度。对2024年2月1日至3月21日收集的数据进行了描述性分析。结果：分析了94名HCPs的数据。大多数是精神科医生（62.8%）或精神科护士（29.8%），他们在专科精神健康诊所/中心（59.6%）或医院(住院病人，36.2%；门诊病人,23.4%)。临床实践的中位持续时间为21.0年。启动aom400 - tis的常见原因是依从性差（85.1%）、复发（59.6%）和高住院率（48.9%）。aom400 - tis的常见处方目标包括改善依从性（70.2%）、预防复发（69.1%）和改善患者生活质量（62.8%）。AOM 400-TIS的障碍是患者不希望两次注射（66.0%），耐受性问题（30.9%），以及对单日高剂量用药的安全性问题（28.7%）。影响aom400 - tis处方的关键因素是既往治疗依从性（55.3%）和疗效（48.9%）。大多数HCPs同意/强烈同意AOM 400-TIS易于使用（79.8%），并且具有与一次注射开始方案相似的安全性/耐受性（69.1%），大多数HCPs对AOM 400-TIS的患者结果满意（84.0%）。结论：欧洲HCPs报告AOM 400-TIS易于使用，耐受性良好，并改善了治疗结果。使用它的障碍包括患者不愿意和感知到的安全问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.